Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Secures $37M Private Equity Funding


HAMBURG, Germany --Sequenom, a transnational pharmacogenomics technology company headquartered here, completed a $37 million financing round through equity funding last week. Participants in the round included Nomura International, Deutsche Bank, Haspa Bank, Euroventures, Vertex Capital, Alafi Capital, and Value Management and Research. Previous investors, including Techno Venture Management, Alpinvest International, Global Life Sciences, Dresdner Kleinwort Benson, and SR One, also participated.

Hubert Koster, Sequenom's president and CEO, said the funding will enable the company to complete full commercial launch of its proprietary DNA analysis products and to expand its manufacturing, sales, and service support structure.

By year's end, the company said it will launch its DNA MassArray Basic System, a modular, semiautomated platform that includes an array mass spectrometer, nanoplotter, and bioinformatics workstation, and its DNA MassArray APL system, which offers robotics and software to meet high-throughput demands in industrial settings.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.